Author: Pat Rippon

Drop in Triglycerides, Drop in A1C

We have another client who has impressive blood work changes after starting IVs. Here’s the scoop.
Client is 68 and female. Had chronically high triglycerides, hypertension, and struggles with A1C and pre-diabetic blood markers. In 25 years of medication and food modification she has never seen improvements like this. Client reports reduction (she claims it has been an “elimination”) in joint pain and arthritis and improved sleep. 

  • Triglycerides went from 173 (high) to 138 (normal)
  • A1C went from 6.8 to 5.9 
  • First draw was August 12th 2021
  • Second draw was October 19th 2021
  • She gets Thrive bags 1x monthly with NAD+ 250mg
  • She combines her IVs with intermittent fasting

At Renew iv we don’t make medical claims nor do we give medical advice. The client who shared the above blood work results felt their IVs have had a positive impact on their blood work.

nad+ therapy and cholesterol

Cholesterol and NAD+ (see the blood work results!)

  • Total cholesterol 232 to 178
  • Triglycerides 432 to 291(in 6 weeks)

The above blood work was shared by a Renew iv client. They came in for a Thrive iv + NAD+ on September 4th. One week after they received their iv they repeated blood work from July 27th. There were no changes in their diet or exercise habits from the initial blood work on July 27th.

At Renew iv we don’t make medical claims nor do we give medical advice. The client who shared the above blood work results felt their iv (especially the NAD+) had a positive impact on their blood work.

Cholesterol and NAD+

The ‘Why’ Behind Renew iv – Getting Personal with the Founder

Renew Movement™ recently launched Renew iv and the ‘why’ behind the business is both heartbreaking and inspiring. The story of how it became involves a long-fought battle against autoimmune disease, food allergies, extreme fatigue, and dozens of baffled doctors. 

The complications and realities of chronic health concerns shadow my past. Dozens of doctors, tests, supplements, and promises began to chip away at my hope while answers remained elusive. However, we’re going to look at what appears to be working, like a small unbelievable miracle. The story requires a tinge of history. History being extreme fatigue (I mean extreme), excessive sleep (10+ hours a night with supplemental 02 due to low oxygenation). I was constantly tired and rarely felt well. 

renew-iv nad therapy

(Ashley O’Connell, Owner/Founder)

Fast forward… I’ve been trying something new and (drumroll) I’m sleeping 6-7 hours a night (not always with oxygen!) AND I have energy during the day. Like, real, get things done, feel okay, kind of energy. I’m pretty sure this is how non-autoimmune people feel, possibly? Dare I say, I feel normal… even a bit spontaneous. I simultaneously feel calmer because the constant reminder of illness is no longer the lens I see the day through. 

What is it? I’m confident it’s the NAD+ (which is an iv) and injections I’ve been taking (along with iv vitamins, especially Vitamin B). I source fresh, high-quality compounded ingredients and source Vitamin C from tapioca instead of corn. I’m extra careful about ingredients and freshness, something I will never compromise on. We have a wonderful Medical Director who oversees the injections and infusions and amazing nurses who provide the services. If this resonates, Google NAD+ or reach out to our team anytime. 

Our COVID Story

My husband, Corin, and I contracted covid. We’re both vaccinated (him Pfizer, me J&J). Neither of us had the vaccine booster when we got sick. Here’s our story.

10/31: Corin felt like he had a cold. He did an at home rapid test. The result was negative.

11/2: Corin thought he might have pneumonia. His lungs were hurting. His second rapid test was negative.

11/3: We went to the doctor’s office to check for pneumonia. His lungs were clear. We ask the doctor to do another covid test. That afternoon we get the call, it’s covid. We immediately shut everything down and got the kids from school. We called everyone we’d been in contact with. Corin was now sleeping 18+ hours a day and feeling terrible. I took myself and our sons for PCR tests. **Corin was so disoriented that he hit a curb and damaged his car coming home from the doctor (first sign of brain fog issues).

11/4: Corin went down hard and was getting sicker by the day. He was waking up for food and home IVs but appeared disoriented and unable to perform small tasks (dropping things and losing his balance). He was becoming dehydrated with a worsening cough. I was checking his pulse ox while he slept – it was holding steady. My results came in- I was positive too.

11/5-7: I presented with a head cold and a minor sore throat – no other symptoms. My husband was much worse and I was very concerned about his “brain fog” symptoms. His pulse ox was in the 90s indicating the brain fog was likely coming from inflammation in his brain. He was getting worse and our doctor was concerned so he was admitted into the ER for a CT scan to rule out a stroke. While he was in the ER they gave him antibodies. The CT showed that he did not have signs of a stroke but he was still experiencing concerning symptoms.

The following weeks were a blur. Our nine year old eventually tested positive but he was asymptomatic. Quarantine felt like forever and I was secretly terrified for my Corin’s health but I was determined to do everything I could to keep him healthy.

“My husband regained all cognitive functioning before we were out of quarantine…”

You might be asking why this story is appearing in a Renew newsletter… I want to talk about NAD+. As you know, I’m a big fan of NAD+ and I get IVs and shots often. NAD+ reduces systemic inflammation and covid can cause inflammatory issues that lead to cytokine storms, loss of taste and smell, brain fog and much more. I went into my covid journey with plenty of NAD+ in my system. My husband didn’t.

I maintained my NAD+ regimen throughout having covid. When Corin was diagnosed he started NAD+ IVs and shots at home. He got an IV every other day with NAD+ and a Myers Cocktail. Corin regained all cognitive functioning before he was out of quarantine.

Covid is complicated and every person’s system is different. I believe that IV hydration with immune boosting vitamins and inflammation fighting NAD+ played a role in minimizing my symptoms and my husband’s quick recovery from brain fog issues. I’m beyond grateful we had access to hydration, nutrients and NAD+ through our covid journey.

Wishing you the best of health.

~ Ashley

Please note that we don’t offer medical advice at Renew and the above is my personal experience, not a medical claim.

Concierge IVs coming soon!

Our journey would have been much different without access to IVs. We have decided to offer concierge home services for IVs. We will be introducing the details in early January.

Therapeutic potential of boosting NAD+ in aging and age-related diseases

Abstract

Nicotinamide adenine dinucleotide (NAD+) is an essential cofactor in all living cells that is involved in fundamental biological processes. NAD+ depletion has been associated with hallmarks of aging and may underlie a wide-range of age-related diseases, such as metabolic disorders, cancer and neurodegenerative diseases. Emerging evidence implicates that elevation of NAD+ levels may slow or even reverse the aspects of aging and also delay the progression of age-related diseases. Here we discuss the roles of NAD+-synthesizing and -consuming enzymes in relationships to aging and major age-related diseases. Specifically, we highlight the contribution of NAD+ depletion to aging and evaluate how boosting NAD+ levels may emerge as a promising therapeutic strategy to counter aging-associated pathologies and/or accelerated aging.

1. Introduction

Nicotinamide adenine dinucleotide (NAD+) is an important cofactor in all living cells that is involved in fundamental biological processes, namely metabolism, cell signalling, gene expression, DNA repair, among others [1][2][3][4]. Originally, Harden and Young described NAD+ in 1906 as a molecular fraction (“cozymase”) that accelerated fermentation in yeast extracts. Over subsequent years, NAD+ was identified as a nucleoside sugar phosphate, which plays a role in redox reactions [5]. However, evidence stemming from recent studies have unveiled numerous roles of NAD+ metabolism on aging and longevity. In particular, an age-dependent decline in NAD+ levels have consistently been reported, possibly due to an imbalance in the synthesis and consumption of NAD+. Decreased levels of NAD+ are associated with the hallmarks of aging as well as several age-related diseases, including metabolic disorders, cancer and neurodegenerative diseases. Replenishment of NAD+ levels via administration of its precursors have been demonstrated to display beneficial effects against aging and age-related diseases. Importantly, boosting NAD+ levels have been shown to extend lifespan of various laboratory animal models including worms, flies, and rodents [3][5][6][7][8].

As a cofactor, NAD+ is found in abundance in the mitochondria, cytoplasm, and nucleus. It is essential for many cellular metabolism pathways that include: glycolysisfatty acid β-oxidation, and the tricarboxylic acid cycle. Whilst the reduced form of NAD+ (NADH) is a primary hydride donor in the production of ATP via anaerobic glycolysis and mitochondrial oxidative phosphorylation (OXPHOS) [6][9]. On the other hand, NAD+ is consumed by the NAD+-dependent sirtuins and the DNA damage sensors poly (ADP-ribose) polymerases (PARPs) in the processes of protein deacetylation and poly-ADP-ribosylation (PARylation), respectively. In addition, NAD+ glycohydrolases (i.e. CD38 and CD157) also consume NAD+ via conversion of NAD+ into ADP-ribose (ADPR) or cyclic-ADPR [1][2][3]. Thus, the importance of NAD+ has expanded from a key element in intermediate metabolism to a critical regulator of multiple cell signalling pathways; and is now a major player contributing to aging and age-related diseases [6].

In mammals, NAD+ is synthetized from a variety of dietary sources, including NAD+ itself (it is metabolized in the gut, then synthesized again in cells) as well as from one or more of its major precursors that include: tryptophan (Trp), nicotinic acid (NA), nicotinamide riboside (NR), nicotinamide mononucleotide (NMN), and nicotinamide (NAM). Based upon the bioavailability of its precursors, there are three pathways for the synthesis of NAD+ in cells: (i) from Trp by the de novo biosynthesis pathway or kynurenine pathway; (ii) from NA in the Preiss–Handler pathway; and (iii) from NAM, NR, and NMN in the salvage pathway [5][6].

Accumulating evidence demonstrates an age-dependent decline in NAD+ levels and associate its depletion to several hallmarks of aging and age-related diseases (Fig. 1[6]. Here, we summarize the roles of NAD+-synthesizing and -consuming enzymes in aging and age-related diseases. Specifically, we highlight the contribution of NAD+ depletion to mammalian aging and evaluate how boosting endogenous NAD+ levels might emerge as a promising therapeutic strategy to counter aging-associated pathologies and/or accelerated aging.

Fig. 1. NAD+ decline at the core of hallmarks of aging. A schematic representation of age-dependent decline in NAD+ levels which contribute to ten hallmarks of aging, namely DNA damage, epigenetic alteration, deregulated nutrient-sensing, loss of proteostasis, altered cellular communication, cellular senescence, stem cell exhaustion, mitochondrial dysfunction, compromised autophagy, and possibly telomere attrition. Figure modified from Fang et al. 2017 [10].

2. Recent progress on the roles of NAD+ in aging

Mounting evidence has indicated that NAD+ levels decline with age in multiple types of tissues, which include the liver, skeletal muscle, adipose tissue, heart, brain, kidney, pancreas, lungs, spleen, skin, as well as extracellular fluids [3][10]. In addition, an age-dependent decline in NAD+ levels in Caenorhabditis elegans (C. elegans), mice, and human post-mortem tissues are reported. Thus, highlighting a universal age-dependent decrease of NAD+ across species. However, it remains elusive whether this is due to increased NAD+ consumption and/or decreased synthesis [6]. In this section, we provide an overview of methods that could potentially boost endogenous levels of NAD+.

2.1. NMN and aging

NMN is a physically stable natural compound that serves as an efficient NAD+ precursor. In mammals, NMN is synthesized from nicotinamide, a form of water-soluble vitamin B3 and 5′-phosphoribosyl-1-pyrophosphate (PRPP), by the rate-limiting enzyme, nicotinamide phosphoribosyl transferase (NAMPT). In addition, it can also be synthesized from NR via NR kinases (NRKs)-mediated phosphorylation reactions. NMN is subsequently converted into NAD+ by NMN adenylyl transferases (NMNATs) [5]. Over the years, it has become increasingly evident that systemic administration of NMN in rodents enhances the biosynthesis of NAD+ in various peripheral tissues including liver, pancreas, adipose tissue, heart, skeletal muscle, kidney, eyes, and blood vessels [5][6][11][12][13][14][15][16][17][18][19]. Furthermore, NMN has also been shown to elevate levels of NAD+ in hypothalamus and hippocampus following an intraperitoneal injection, thereby indicating its ability to penetrate the blood-brain barrier (BBB) [20][21]. More importantly, long-term (1-year) oral administration of NMN (up to 300 mg/kg) has recently been shown to be well tolerated without any obvious deleterious or toxic effects in normal wild type C57BL/6 mice [22].

NMN has been shown to have remarkable beneficial effects that counter normal aging. In models of aging, long-term administration of NMN protects against age-associated functional decline as demonstrated by increases in energy metabolism, insulin sensitivitylipid metabolism, mitochondrial oxidative metabolism, eye function, bone density and immune function [10][22]. On the other hand, it suppressed age-related changes in gene expression and adipose tissue inflammation [22]. Moreover, it has been shown to maintain neural stem/progenitor cell population and restore skeletal muscle mitochondrial function as well as arterial function in aged mice [15][19][20]. In addition, loss of enzymes involved in NAD+ synthesis, namely NAMPT during the process of aging, led to decrease in NAD+ content and reduced SIRT1 activity; consequently, promoted cellular senescence in retinal pigment epithelium, which performs numerous functions critical to retinal health and visual function [23].

NMN administration may counteract age-predisposed metabolic diseases and neurodegeneration. In age-related pathophysiological conditions, NMN ameliorated impairments in glucose tolerance and promoted insulin secretion/sensitivity in age- or diet-induced diabetic mice, Nampt+/− mice, as well in aged wild-type and β cell-specific Sirt1-overexpressing (BESTO) mice [5][6][11][24][25][26]. Likewise, promotion and overexpression of the mitochondrial Nmnat3 in mice, also involved in NAD+ biosynthesis, resulted in improved glucose tolerance during the process of aging as well as in models of high-fat induced obesity [27]. The beneficial effect was suggested to be a result of improved mitochondrial function and by an independent mechanism of NAD+–SIRT1–PGC1α axis, which despite previously being reported to contribute to improved mitochondrial function, was not activated in these transgenic mice despite elevated levels of NAD+ [27]. Furthermore, NMN protects the heart and brain from ischaemia-induced damage [28][29]. In rodent models of Alzheimer’s disease (AD), administration of NMN decreased AD-associated β-amyloid (Aβ) pathology and improved cognitive function. In addition, it restored mitochondrial function and ameliorated inflammation, synaptic loss as well as protected against neuronal cell death [30][31][32]. The beneficial effect of NMN was also evident in premature aging conditions as demonstrated by extended lifespan and improved healthspan in the C. elegans model of xeroderma pigmentosum group A (XPA, a nucleotide excision DNA repair (NER) disorder with severe neurodegeneration) [33], and Ataxia telangiectasia (A-T, due to mutation of ATM which encodes a master regulator of DNA damage response) [34][35]. Moreover, in mice with hypomorphic BubR1 (a mitotic check-point kinase) exhibited characteristics of premature aging as evidenced by shorter lifespan, which was restored by NMN supplementation [17]. Altogether, these findings highlight NMN induced restoration of NAD+ levels serve as beneficial therapeutic strategy in countering aging as well as age-related pathological conditions in animal models.

2.2. NR and aging

NR is a natural NAD+ precursor. It can directly be converted into NMN via the activity of NRKs, thereby bypassing the requirement of the NAMPT in the salvage pathway, and therefore offers to provide an additional pathway for elevation of NAD+ levels. Similar to NMN, NR also exhibited beneficial effects in protection against aging and age-related diseases. It has been shown to promote longevity as well improve healthspan in multiple laboratory animal models [36][37][38][39][40][41]. In age-related disease, in particular obesity, diabetes and cardiovascular conditions NR was able to decrease weight gain, improve glucose tolerance and increase survival rates, respectively in rodents [42][43][44]. In addition, in models of diabetes and high-fat diet, NR was able to improve metabolic function and reduce lipid accumulation as well as increasing lifespan [40][44][45][46]. Furthermore, supplementation of NR reversed the progressive wasting syndrome and restored endurance in Nampt skeletal muscle knockout micemdx model of Duchenne’s muscular dystrophy [47][48].

NR ameliorates neurodegeneration in animal models. In animal models of age-related neurodegenerative diseases such as AD and Parkinson’s disease (PD), NR has been shown to improve memory, learning, motor function and mitochondrial function as well as protected against neuronal cell death [49][50][51][52]. In particular, chronic NR administration in the amyloidogenic models of AD delayed the development and progression of Aβ pathology in AD mice, SH-SY5Y cells, and AD C. elegans [50][52]. In addition, it was able to promote longevity and inhibit/delay cognitive decline in AD C. elegans and mice, with the enhanced process of mitochondrial proteostasis and modulation of β-secretase 1 (BACE-1) activity via peroxisome proliferator-activated receptor-gamma coactivator 1 (PGC)-1alpha highlighted as possible underlying mechanisms [50][52]. Further evidence reinforcing the beneficial effects of NR as a therapeutic strategy in AD was provided by a recent study using triple transgenic model of AD (3 × Tg), which exhibited not only reduced phosphorylated tau pathology and inhibited cognitive decline; but also, normalised AD-associated neuroinflammation and synaptic dysfunction. Moreover, DNA damage was reduced, in addition, following chronic administration of NR in a DNA repair-deficient 3 × Tg/Polβ +/− mouse model [6][51]. The underlying mechanism proposed was the reduction in DNA damage results in reduced activity of NAD+ consuming enzyme PARPs that is involved in DNA repair; thereby increase in the levels of NAD+, which in turn contributes to neurogenesis and inhibits AD-associated pathology, neuroinflammation and mitochondrial dysfunction [51]. Likewise, NR treated induced pluripotent stem cells (iPSCs) derived from PD patients harbouring mutations in the lysosomal enzyme β-Glucocerebrosidase (GBA) gene (GBA-PD), the most common genetic risk for PD, resulted in elevated levels of NAD+ and NAM which coincided with improved mitochondrial morphology and function [49][53]Mitophagy was suggested to be a possible mechanism promoted by NR, which may underlie improved mitochondrial quality control [49]. In addition, flies model of GBA-PD expressing human N370S GBA raised on food containing NR displayed improved motor function and significantly decline in loss of dopamine-containing neuronal population [49]. Additionally, NR has shown significant neuroprotection in a series of DNA repair-deficient premature aging diseases, including XPA, A-T, and Cockayne syndrome (CS, due to impairment of NER) [33][34][54].

2.3. NAM and aging

NAM is also a precursor for NAD+ and a key molecule involved in energy metabolism. Low doses of NAM have been shown to increase lifespan in yeast and C. elegans, however, higher doses have been associated with reduced lifespan via inhibition of Sir2 activity [39][55][56][57][58]. In models of aging and high fat diet-induced obesity, NAM improved healthspan although it failed to extend lifespan as illustrated by comparable mean and maximum lifespan [59]. In the model of obesity, it has able to restore glucagon storage to similar levels as age-matched standard-diet mice as well as ameliorate diet-induced hepatosteatosisoxidative stress and inflammation [59]. It was suggested that the beneficial impact of NAM may be attributes to improved mitochondrial function and countering age and high fat diet induced DNA damage [59]. Further evidence reinforcing the beneficial impact of NAM stemmed from a mouse model of glaucoma, which inhibited the development glaucoma in the eyes [60]. Moreover, these findings were replicated by Nmnat1 gene therapy whereby an intravitreal administration of adeno-associated virus AAV2.2 carrying a plasmid to overexpress murine Nmnat1 under a CMV promoter was performed in D2 eyes [60]. The improvement of mitochondrial health and metabolism was suggested to be the underlying mechanism for countering glaucoma mediated by NAM supplementation and Nmnat1 gene therapy [60].

3. Other approaches to regulate NAD+

3.1. PARP inhibition

The NAD+ consuming enzymes, PARPs, cleave NAD+ into NAM and ADP-ribose (ADPR), as a result generating a chain of ADPR. PARP1 is the most abundant PARPs, which is ubiquitously expressed and is a major consumer of NAD+ in response to DNA damage whereby it contributes to facilitation of the DNA repair process [61]. Both PARPs and sirtuins share NAD+ as a common substrate thus compete for its consumption. It has been reported that PARP1 activity increased with the inevitable process of aging possibly due accumulation of DNA damage [33]. Consequently, the NAD+ pool is depleted which results in reduced activity of sirtuins [62]. Evidence stemming from genetic deletion of PARP1 in mice as well as pharmacological inhibition of PARPs revealed increase in NAD+ content and enhanced activities of sirtuins, in particular SIRT1 and SIRT6 [33][34][39]. Elevated SIRT1 activity was associated with increased mitochondrial content and oxidative metabolism as well as protection against metabolic dysfunction, DNA damage, and neurodegeneration [4][10][62].

In addition, increased PARP1 activity has been reported in animal models of age-related neurodegenerative diseases, namely AD and PD [63][64][65]. Deletion of PARP1 in AD mice protected against cognitive decline as well as attenuated neuroinflammation and Aβ-induced neurotoxicity [66]. In PD rodents, PARP1 pharmacological inhibitors or deletion resulted in resistance to the toxic effects and loss of dopamine-containing neurons in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 6-hydroxydopamine (6-OHDA), respectively [67][68][69]. Thus, implicating the contribution of PARP1 hyperactivity in processes leading to neurodegeneration. Moreover, hyperactivity of PARP1 is reported in models of premature aging that resulted decrease in SIRT1 activity, a feature that was reversed by replenishment of NAD+ using its precursors [33][34]. Therefore, a potential therapeutic counter for depleted NAD+ pool in aging and age-related diseases could be inhibition of its consumer, PARPs, which will enable activity of sirtuins that plays a pivotal role in regulating cellular processes.

3.2. CD38 inhibition

CD38 is one of the primary NADases in mammals. It can modulate the levels of NAD+ via hydrolysis of NAD+ itself as well degradation of its precursors, NMN and NR. Primarily, CD38 hydrolyses NAD+ to produce of ADPR and NAM [70][71][72]. It is a key player in several physiological processes, including nuclear Ca2+ homoeostasis, immunity, inflammation, glucose and lipid homoeostasis, transferring of mitochondria from astrocytes to neurons, as well as social behaviour [6][73][74][75][76][77]. An age-dependent increase in levels of CD38 protein has been reported in multiple tissues and organs, which as a result contributes to NAD+ decline [78]. Therefore, CD38-dependent modulation of NAD+ can alter the activity of NAD+-consuming enzymes and affect cellular signalling and metabolism [71][72]. Inhibition of CD38 can also promote NAD+ levels and improve glucose and lipid metabolism, which protects against age- and diet-induced diabetes and obesity [72][75]. In APP/PS1 model of AD, CD38 depletion resulted in elevation of NAD+ levels that were associated with decrease in Aβ pathology and associated neuroinflammation accompanied by improvement spatial learning behaviour [79]. However, due to the reported important neuroprotective activities of CD38, further stringent and comprehensive evaluation of the procedures of CD38 inhibition as a safe anti-aging strategy [76][77].

3.3. NNMT knockdown

Nicotinamide N-methyltransferase (NNMT) catalyses the methylation of NAM N1-methyl-2- pyridone-5-carboxamide (2py) and N1-methyl-4-pyridone-3-carboxamide (4py) using the universal methyl donor S-adenosyl methionine (Met) (SAM). Both products of NAM methylation are eventually excreted in the urine; thus, NNMT removes NAM from the NAD+ biosynthesis pathway and thereby contributes to decrease in levels of NAD+ [80]. It is predominantly expressed in the liver and adipose tissue but is also found in other tissues including kidney, lung, muscle, heart, brain, and tumour cells. NNMT has been shown to be involved in various disease conditions such as metabolic disorders, neurodegenerative diseases and cancer [80]. In conditions such as obesity and diabetes, NNMT levels have been reported to be upregulated significantly, which in turn are associated with the disease phenotype [81][82]. In fact, genetic knockdown as well as pharmacological inhibition of NNMT was shown to be beneficial in protection against obesity in rodent models of obesity [83][84].

3.4. Genetic promotion of NAD+ biosynthesis

In addition to abovementioned techniques that have shown to enhance NAD+ biosynthesis, genetic tools in the form of Lactobacillus brevis (LbNOX), a water-forming NADH oxidase, has been demonstrated to also induce an increase in compartment-specific levels of NAD+/NADH ratio in HeLa cells [85]. It catalyses a four-electron reduction of oxygen to water (2 NADH + 2H+ + O2 → 2 NAD+ + 2 H2O) [85][86]. The NAD+/NADH ratio plays a role in cellular metabolism by affecting the activity of NAD+-dependent enzymes such as sirtuins. LbNOX was shown to ameliorate proliferative and metabolic defects induced by a dysfunctional electron transport chain (ETC) by recycling the pool of NAD+ [85]. This, therefore offers to be a novel approach whereby NAD+ levels could potentially be boosted via genetic manipulation in order to understand the fundamental molecular mechanisms in models of aging and age-related diseases.

4. Methods to detect subcellular NAD+

In view of the importance of NAD+ in life, aging, and diseases, it is necessary to accurately detect subcellular NAD+ levels to further unveil its intracellular functions as well as to develop sub-cellular organelle-targeted therapeutic approaches. Traditionally, several assays, such as high-performance liquid chromatography (HPLC)-based methods (e.g., HPLC/MALDI/MS) and fluorometric-based commercial kits have been utilised to detect whole NAD+ [26][48] at both cellular levels and/or sub-cellular levels (by isolating sub-cellular fractions ahead). There have some challenges of using these methods to accurately detect sub-cellular NAD+ levels because of the highly instability of NAD+ as well as impossibility of NAD+ detection in live cells/tissues. The recent development of genetically encoded fluorescent biosensors such as SoNar and a biosensor with a bipartite NAD+-binding domain have enabled imaging of relative levels of free NAD+ in the subcellular compartments [87][88]. Quantification of NAD+ using fluorescent biosensor targeted to different compartments of mammalian cells showed that mitochondria contain more than twice as much free NAD+ as other compartments [87]. Specifically, the concentration of NAD+ was reported to be approximately 110 μM in the cytoplasm and the nucleus relative to 230 μM in the mitochondrion [87]. These levels are consistent with other reports demonstrating that, in highly metabolically active, post mitotic cells, such as neurons, mitochondria have higher NAD+ levels compared with other sub-cellular compartments [1]. It was further demonstrated genetic and pharmacologic inhibition of NAMPT result in a reduction in NAD+ concentration in all compartments, but depletion of mitochondrial NAD+ occurred at a slower rate. Furthermore, the nuclear and cytoplasmic pools were shown to be readily exchangeable, whilst the mitochondrial pool may maintain mitochondrial NAD+ levels via NAD+ biogenesis by mitochondrial isoform NMNAT3 and import from the cytoplasm [87]. Another recent development has been offered in the form of NAD+ flux quantification that is isotope-tagged and used for analysis of NAD+ metabolism. It demonstrated that approximately 50% decrease in NAD+ consumption following treatment with SIRT1/2 and PARP1/2 inhibitors; thereby implicating both are major consumers of NAD+ [89]. The use of such approaches in models of aging and age-related diseases in combination with NAD+ promoting methods would allow the identification of subcellular localisation as well as consumption, which in turn would allow to identify the underlying molecular mechanisms and pathways attributed to NAD+ benefits.

5. Clinical translation

Encouraged by significant and replicable benefits of NAD+ precursors, NR and NMN, in aging and disease animal models, a series of clinical trials of NR and NMN in normal aged population and individuals with diseases have been performed [10]. NAD+ precursors, in particular NR has been demonstrated to elevate blood concentration of NAD+ in healthy individuals in a dose-dependent manner and without any toxic effects [90]. In particular, single oral self-administration of NR (1000 mg) over a period of seven days in a 52 years old male increased blood concentration of NAD+ by 2.7-folds and 45.5-fold increase in nicotinic acid adenine dinucleotide (NAAD), an NAD+ biosynthesis intermediate [90]. In addition, a randomized double-blind pharmacokinetic study of single oral administration NR (doses: 100 mg, 300 mg, and 1000 mg) with seven-days gap conducted in 12 healthy patients (aged 30–55 years old) revealed a dose-dependent increase in NAD+ and NAAD levels, with no reported adverse effects [90]. The encouraging results in animal models of aging and age-related diseases of chronic administration of NAD+ precursors have led to studies in humans [91][92]. An eight-week randomized, double-blinded, placebo-controlled study in 120 healthy adults (60–80 years old) demonstrated NR (250 mg and 500 mg) induced dose-dependent increase of blood NAD+ level that becomes apparent after 4-weeks and is sustained till the end of the study [91]. Importantly, no serious adverse effects were reported, thereby implicating the chronic administration of NR is a safe and effective way to increase NAD+ levels [91]. These findings are reinforced by a 2 × 6-week randomized, double-blind, placebo-controlled crossover clinical trial conducted in 55–79 years old individuals that showed NR (oral 500 mg, twice a day) to be well tolerated and able to effectively elevates NAD+ levels in healthy adults [92]. Moreover, it was able to reduce systolic blood pressure and aortic stiffness, which are considered measures of cardiovascular disease [92]. Thus, not only the NAD+ precursors are safely administrated but they may also recapitulate the beneficial effects that were evident in animal models, which is an exciting prospect for future clinical trials. However, in conditions such as pancreatic cancer, cell growth has been shown to be dependent of the NAD+ salvage pathway [93]. Hence, inhibition of NAD+ synthesis (via Nampt inhibition) and/or promotion of its consumption (via CD38 NADase) prevented cancer cell growth [93][94]. Therefore, implicating that there should be a thorough evaluation for the use of approaches that promote NAD+ biosynthesis as it may be contributor rather than a counter-mechanism in certain conditions. Clinical trials of NAD+ precursors on age-related diseases, such as diabetes, premature aging diseases, and neurodegenerative diseases are in progress [10].

6. Outstanding questions and future perspectives

Age is the primary cause of the majorly of human diseases and interventional strategies/therapeutics targeting on human aging is arguably the most efficient approach to achieve healthy aging and the improvement of the quality of life worldwide. Although, maintaining a healthy diet, fasting, and exercise may improve the quality of life, it may not be feasible option for all individuals. Therefore, the beneficial effects of NAD+ discussed in the present review, highlight possible ways for improving the quality of life via hindering numerous pathological hallmarks of aging and thereby improving the quality of life and delay age-related diseases (summarized in Fig. 2). Preclinical evidence of NAD+ replenishment that could potentially delay and/or prevent metabolic conditions, hearing loss, muscle atrophy, and cognitive decline are really encouraging for future perspectives. Moreover, NAD+ precursors, in particular NR has been shown to be safely administrated and also able to demonstrate improvement of cardiovascular functions in human. Thus, implicating a possible translational aspect of preclinical benefits of NAD+ supplementation, which is an exciting prospect and opens avenues for future studies to test the impact of elevated NAD+ biosynthesis in aging and age-associated diseases in human.

Fig. 2. Physiological and pharmacological strategies for boosting NAD+ levels. Inhibiting the age-related decline in NAD+ levels is critical for preventing age- or disease-related frailties. Physiological strategies that could potentially boost NAD+ levels include exercise, fasting, and maintaining a healthy diet. Pharmacologically, boosting NAD+ can be achieved via either supplementation of its precursors, NR and NMN, or inhibition of its consumers by use of CD38 and PARPs inhibitors. Figure modified from Fang et al. 2017 and Fivenson et al. 2017 [10][95].

Despite extensive research on NAD+ biosynthesis and its implications in health and disease, there are major questions that are yet to be explored. Firstly, what levels of NAD+ are to be associated with healthy aging and age-related diseases? In particular, it is of great relevance to elucidate organ and sub-cellular localisation as well levels of NAD+ in health and disease. Such observations would allow to map health- and disease-specific alterations of NAD+, which could be utilised to develop therapeutic interventions that promote NAD+ in a region-specific manner as a counter-mechanism. Decline in NAD+ has been implicated during the process of aging and age-associated diseases, thereby may be affect various processes that are likely to key contributors and drivers of associated dysfunction. Thus, preclinical studies driven towards unveiling the pathways and mechanisms underlying the beneficial effects of NAD+ replenishment in healthy aging and models of disease are required in order to understand how NAD+ contributes to delay and/or prevent hallmarks associated with aging. In particular, it is important to elucidate whether individual or multiple hallmark(s) mechanisms associated with aging are countered by NAD+ replenishment. This would allow understanding of the mode of NAD+ action and the interconnection and contribution of the various hallmarks of aging. NAD+ precursors have thus far shown to be safely and effectively administrated in healthy old humans, elevating NAD+ levels in blood, but its safety and tolerance is yet to be determined in individuals with age-related diseases. Therefore, future clinical trials are required to assess the safety of NAD+ precursors in patients with age-associated diseases such as diabetes and AD. Though, as abovementioned, careful evaluation of the role of NAD+, whether friend or foe in disease, must be taken into account for each disease-condition. Altogether, NAD+ replenishment may serve as a potential therapeutic strategy for aging and multiple conditions to improve the quality of life of the increasing aged population.

Conflicts of interest

The authors declare there is no conflict of interest.

Acknowledgements

This research was supported by the HELSE SøR-ØST (E.F.F., #2017056), The Research Council of Norway (E.F.F., #262175 and #277813), and two NIA Intra-laboratory grants (2016, 2017 to E.F.F. and V.A.B.). The E.F.F. laboratory has CRADA arrangements with ChromaDex. We thank Øystein Horgmo (Senior Photographer, Medical Photography and Illustration Service, UiO) for making some elements in Fig. 1Fig. 2.

References

[1]C. Canto, K.J. Menzies, J. AuwerxNAD(+) metabolism and the control of energy homeostasis: a balancing act between mitochondria and the nucleusCell Metabol., 22 (2015), pp. 31-53ArticleDownload PDFView Record in ScopusGoogle Scholar

[2]G. Magni, A. Amici, M. Emanuelli, G. Orsomando, N. Raffaelli, S. RuggieriEnzymology of NAD+ homeostasis in manCell. Mol. Life Sci., 61 (2004), pp. 19-34View Record in ScopusGoogle Scholar

[3]K. Yaku, K. Okabe, T. NakagawaNAD metabolism: implications in aging and longevityAgeing Res. Rev., 47 (2018), pp. 1-17ArticleDownload PDFView Record in ScopusGoogle Scholar

[4]E. VerdinNAD(+) in aging, metabolism, and neurodegenerationScience, 350 (2015), pp. 1208-1213 View PDFCrossRefView Record in ScopusGoogle Scholar

[5]J. Yoshino, J.A. Baur, S.I. ImaiNAD(+) intermediates: the biology and therapeutic potential of NMN and NRCell Metabol., 27 (2018), pp. 513-528ArticleDownload PDFView Record in ScopusGoogle Scholar

[6]M. Misiak, R. Vergara Greeno, B.A. Baptiste, P. Sykora, D. Liu, S. Cordonnier, et al.DNA polymerase beta decrement triggers death of olfactory bulb cells and impairs olfaction in a mouse model of Alzheimer’s diseaseAging Cell, 16 (2017), pp. 162-172 View PDFCrossRefView Record in ScopusGoogle Scholar

[7]E. Katsyuba, J. AuwerxModulating NAD(+) metabolism, from bench to bedsideEMBO J., 36 (2017), pp. 2670-2683 View PDFCrossRefView Record in ScopusGoogle Scholar

[8]L. Rajman, K. Chwalek, D.A. SinclairTherapeutic potential of NAD-boosting molecules: the in vivo evidenceCell Metabol., 27 (2018), pp. 529-547ArticleDownload PDFView Record in ScopusGoogle Scholar

[9]D.C. WallaceMitochondria and cancerNat. Rev. Cancer, 12 (2012), pp. 685-698 View PDFCrossRefView Record in ScopusGoogle Scholar

[10]E.F. Fang, S. Lautrup, Y. Hou, T.G. Demarest, D.L. Croteau, M.P. Mattson, et al.NAD+ in aging: molecular mechanisms and translational implicationsTrends Mol. Med., 23 (2017), pp. 899-916ArticleDownload PDFView Record in ScopusGoogle Scholar

[11]J. Yoshino, K.F. Mills, M.J. Yoon, S. ImaiNicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in miceCell Metabol., 14 (2011), pp. 528-536ArticleDownload PDFView Record in ScopusGoogle Scholar

[12]C.B. Peek, A.H. Affinati, K.M. Ramsey, H.Y. Kuo, W. Yu, L.A. Sena, et al.Circadian clock NAD+ cycle drives mitochondrial oxidative metabolism in miceScience, 342 (2013), Article 1243417 View PDFCrossRefView Record in ScopusGoogle Scholar

[13]K.L. Stromsdorfer, S. Yamaguchi, M.J. Yoon, A.C. Moseley, M.P. Franczyk, S.C. Kelly, et al.NAMPT-mediated NAD(+) biosynthesis in adipocytes regulates adipose tissue function and multi-organ insulin sensitivity in miceCell Rep., 16 (2016), pp. 1851-1860ArticleDownload PDFView Record in ScopusGoogle Scholar

[14]G. Karamanlidis, C.F. Lee, L. Garcia-Menendez, S.C. Kolwicz Jr., W. Suthammarak, G. Gong, et al.Mitochondrial complex I deficiency increases protein acetylation and accelerates heart failureCell Metabol., 18 (2013), pp. 239-250ArticleDownload PDFView Record in ScopusGoogle Scholar

[15]A.P. Gomes, N.L. Price, A.J. Ling, J.J. Moslehi, M.K. Montgomery, L. Rajman, et al.Declining NAD(+) induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during agingCell, 155 (2013), pp. 1624-1638ArticleDownload PDFView Record in ScopusGoogle Scholar

[16]Y. Guan, S.R. Wang, X.Z. Huang, Q.H. Xie, Y.Y. Xu, D. Shang, et al.Nicotinamide mononucleotide, an NAD(+) precursor, rescues age-associated susceptibility to AKI in a sirtuin 1-dependent mannerJ. Am. Soc. Nephrol., 28 (2017), pp. 2337-2352 View PDFView Record in ScopusGoogle Scholar

[17]B.J. North, M.A. Rosenberg, K.B. Jeganathan, A.V. Hafner, S. Michan, J. Dai, et al.SIRT2 induces the checkpoint kinase BubR1 to increase lifespanEMBO J., 33 (2014), pp. 1438-1453 View PDFCrossRefView Record in ScopusGoogle Scholar

[18]J.B. Lin, S. Kubota, N. Ban, M. Yoshida, A. Santeford, A. Sene, et al.NAMPT-mediated NAD(+) biosynthesis is essential for vision in miceCell Rep., 17 (2016), pp. 69-85ArticleDownload PDFView Record in ScopusGoogle Scholar

[19]N.E. de Picciotto, L.B. Gano, L.C. Johnson, C.R. Martens, A.L. Sindler, K.F. Mills, et al.Nicotinamide mononucleotide supplementation reverses vascular dysfunction and oxidative stress with aging in miceAging Cell, 15 (2016), pp. 522-530 View PDFView Record in ScopusGoogle Scholar

[20]L.R. Stein, S. ImaiSpecific ablation of Nampt in adult neural stem cells recapitulates their functional defects during agingEMBO J., 33 (2014), pp. 1321-1340 View PDFView Record in ScopusGoogle Scholar

[21]M.J. Yoon, M. Yoshida, S. Johnson, A. Takikawa, I. Usui, K. Tobe, et al.SIRT1-mediated eNAMPT secretion from adipose tissue regulates hypothalamic NAD+ and function in miceCell Metabol., 21 (2015), pp. 706-717ArticleDownload PDFView Record in ScopusGoogle Scholar

[22]K.F. Mills, S. Yoshida, L.R. Stein, A. Grozio, S. Kubota, Y. Sasaki, et al.Long-term administration of nicotinamide mononucleotide mitigates age-associated physiological decline in miceCell Metabol., 24 (2016), pp. 795-806ArticleDownload PDFView Record in ScopusGoogle Scholar

[23]R.N. Jadeja, F.L. Powell, M.A. Jones, J. Fuller, E. Joseph, M.C. Thounaojam, et al.Loss of NAMPT in aging retinal pigment epithelium reduces NAD(+) availability and promotes cellular senescenceAging (Albany NY), 10 (6) (2018), pp. 1306-1323 View PDFCrossRefView Record in ScopusGoogle Scholar

[24]P.W. Caton, J. Kieswich, M.M. Yaqoob, M.J. Holness, M.C. SugdenNicotinamide mononucleotide protects against pro-inflammatory cytokine-mediated impairment of mouse islet functionDiabetologia, 54 (2011), pp. 3083-3092 View PDFCrossRefView Record in ScopusGoogle Scholar

[25]K.M. Ramsey, K.F. Mills, A. Satoh, S. ImaiAge-associated loss of Sirt1-mediated enhancement of glucose-stimulated insulin secretion in beta cell-specific Sirt1-overexpressing (BESTO) miceAging Cell, 7 (2008), pp. 78-88 View PDFCrossRefView Record in ScopusGoogle Scholar

[26]J.R. Revollo, A. Korner, K.F. Mills, A. Satoh, T. Wang, A. Garten, et al.Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzymeCell Metabol., 6 (2007), pp. 363-375ArticleDownload PDFView Record in ScopusGoogle Scholar

[27]M. Gulshan, K. Yaku, K. Okabe, A. Mahmood, T. Sasaki, M. Yamamoto, et al.Overexpression of Nmnat3 efficiently increases NAD and NGD levels and ameliorates age-associated insulin resistanceAging Cell (2018), Article e12798 View PDFCrossRefView Record in ScopusGoogle Scholar

[28]T. Yamamoto, J. Byun, P. Zhai, Y. Ikeda, S. Oka, J. SadoshimaNicotinamide mononucleotide, an intermediate of NAD+ synthesis, protects the heart from ischemia and reperfusionPLoS One, 9 (2014), Article e98972 View PDFCrossRefView Record in ScopusGoogle Scholar

[29]J.H. Park, A. Long, K. Owens, T. KristianNicotinamide mononucleotide inhibits post-ischemic NAD(+) degradation and dramatically ameliorates brain damage following global cerebral ischemiaNeurobiol. Dis., 95 (2016), pp. 102-110ArticleDownload PDFView Record in ScopusGoogle Scholar

[30]A.N. Long, K. Owens, A.E. Schlappal, T. Kristian, P.S. Fishman, R.A. SchuhEffect of nicotinamide mononucleotide on brain mitochondrial respiratory deficits in an Alzheimer’s disease-relevant murine modelBMC Neurol., 15 (2015), p. 19 View PDFView Record in ScopusGoogle Scholar

[31]X. Wang, X. Hu, Y. Yang, T. Takata, T. SakuraiNicotinamide mononucleotide protects against beta-amyloid oligomer-induced cognitive impairment and neuronal deathBrain Res., 1643 (2016), pp. 1-9ArticleDownload PDFCrossRefView Record in ScopusGoogle Scholar

[32]Z. Yao, W. Yang, Z. Gao, P. JiaNicotinamide mononucleotide inhibits JNK activation to reverse Alzheimer diseaseNeurosci. Lett., 647 (2017), pp. 133-140ArticleDownload PDFView Record in ScopusGoogle Scholar

[33]E.F. Fang, M. Scheibye-Knudsen, L.E. Brace, H. Kassahun, T. SenGupta, H. Nilsen, et al.Defective mitophagy in XPA via PARP-1 hyperactivation and NAD(+)/SIRT1 reductionCell, 157 (2014), pp. 882-896ArticleDownload PDFView Record in ScopusGoogle Scholar

[34]E.F. Fang, H. Kassahun, D.L. Croteau, M. Scheibye-Knudsen, K. Marosi, H. Lu, et al.NAD+ replenishment improves lifespan and healthspan in ataxia telangiectasia models via mitophagy and DNA repairCell Metabol., 24 (2016), pp. 566-581ArticleDownload PDFView Record in ScopusGoogle Scholar

[35]E.F. Fang, V.A. BohrNAD+: the convergence of DNA repair and mitophagyAutophagy, 13 (2017), pp. 442-443 View PDFCrossRefView Record in ScopusGoogle Scholar

[36]B. Poljsak, I. MilisavNAD+ as the link between oxidative stress, inflammation, caloric restriction, exercise, DNA repair, longevity, and health spanRejuvenation Res., 19 (5) (2016), pp. 406-413 View PDFCrossRefView Record in ScopusGoogle Scholar

[37]P. Belenky, F.G. Racette, K.L. Bogan, J.M. McClure, J.S. Smith, C. BrennerNicotinamide riboside promotes Sir2 silencing and extends lifespan via Nrk and Urh1/Pnp1/Meu1 pathways to NAD+Cell, 129 (2007), pp. 473-484ArticleDownload PDFView Record in ScopusGoogle Scholar

[38]S.P. Lu, M. Kato, S.J. LinAssimilation of endogenous nicotinamide riboside is essential for calorie restriction-mediated life span extension in Saccharomyces cerevisiaeJ. Biol. Chem., 284 (2009), pp. 17110-17119ArticleDownload PDFView Record in ScopusGoogle Scholar

[39]L. Mouchiroud, R.H. Houtkooper, N. Moullan, E. Katsyuba, D. Ryu, C. Canto, et al.The NAD(+)/sirtuin pathway modulates longevity through activation of mitochondrial UPR and FOXO signalingCell, 154 (2013), pp. 430-441ArticleDownload PDFView Record in ScopusGoogle Scholar

[40]H. Zhang, D. Ryu, Y. Wu, K. Gariani, X. Wang, P. Luan, et al.NAD(+) repletion improves mitochondrial and stem cell function and enhances life span in miceScience, 352 (2016), pp. 1436-1443 View PDFCrossRefView Record in ScopusGoogle Scholar

[41]F. Tsang, C. James, M. Kato, V. Myers, I. Ilyas, M. Tsang, et al.Reduced Ssy1-Ptr3-Ssy5 (SPS) signaling extends replicative life span by enhancing NAD+ homeostasis in Saccharomyces cerevisiaeJ. Biol. Chem., 290 (2015), pp. 12753-12764ArticleDownload PDFView Record in ScopusGoogle Scholar

[42]C. Canto, R.H. Houtkooper, E. Pirinen, D.Y. Youn, M.H. Oosterveer, Y. Cen, et al.The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesityCell Metabol., 15 (2012), pp. 838-847ArticleDownload PDFView Record in ScopusGoogle Scholar

[43]W. Xu, T. Barrientos, L. Mao, H.A. Rockman, A.A. Sauve, N.C. AndrewsLethal cardiomyopathy in mice lacking transferrin receptor in the heartCell Rep., 13 (2015), pp. 533-545ArticleDownload PDFView Record in ScopusGoogle Scholar

[44]S.A. Trammell, B.J. Weidemann, A. Chadda, M.S. Yorek, A. Holmes, L.J. Coppey, et al.Nicotinamide riboside opposes type 2 diabetes and neuropathy in miceSci. Rep., 6 (2016), p. 26933 View PDFView Record in ScopusGoogle Scholar

[45]K. Gariani, K.J. Menzies, D. Ryu, C.J. Wegner, X. Wang, E.R. Ropelle, et al.Eliciting the mitochondrial unfolded protein response by nicotinamide adenine dinucleotide repletion reverses fatty liver disease in miceHepatology, 63 (2016), pp. 1190-1204 View PDFCrossRefView Record in ScopusGoogle Scholar

[46]C.C. Zhou, X. Yang, X. Hua, J. Liu, M.B. Fan, G.Q. Li, et al.Hepatic NAD(+) deficiency as a therapeutic target for non-alcoholic fatty liver disease in ageingBr. J. Pharmacol., 173 (2016), pp. 2352-2368 View PDFCrossRefView Record in ScopusGoogle Scholar

[47]D. Ryu, H. Zhang, E.R. Ropelle, V. Sorrentino, D.A. Mazala, L. Mouchiroud, et al.NAD+ repletion improves muscle function in muscular dystrophy and counters global PARylationSci. Transl. Med., 8 (2016), p. 361ra139 View PDFCrossRefView Record in ScopusGoogle Scholar

[48]D.W. Frederick, E. Loro, L. Liu, A. Davila Jr., K. Chellappa, I.M. Silverman, et al.Loss of NAD homeostasis leads to progressive and reversible degeneration of skeletal muscleCell Metabol., 24 (2016), pp. 269-282ArticleDownload PDFView Record in ScopusGoogle Scholar

[49]D.C. Schondorf, D. Ivanyuk, P. Baden, A. Sanchez-Martinez, S. De Cicco, C. Yu, et al.The NAD+ precursor nicotinamide riboside rescues mitochondrial defects and neuronal loss in iPSC and fly models of Parkinson’s diseaseCell Rep., 23 (2018), pp. 2976-2988ArticleDownload PDFView Record in ScopusGoogle Scholar

[50]B. Gong, Y. Pan, P. Vempati, W. Zhao, L. Knable, L. Ho, et al.Nicotinamide riboside restores cognition through an upregulation of proliferator-activated receptor-gamma coactivator 1alpha regulated beta-secretase 1 degradation and mitochondrial gene expression in Alzheimer’s mouse modelsNeurobiol. Aging, 34 (2013), pp. 1581-1588ArticleDownload PDFView Record in ScopusGoogle Scholar

[51]Y. Hou, S. Lautrup, S. Cordonnier, Y. Wang, D.L. Croteau, E. Zavala, et al.NAD(+) supplementation normalizes key Alzheimer’s features and DNA damage responses in a new AD mouse model with introduced DNA repair deficiencyProc Natl. Acad. Sci. U. S. A., 115 (2018), pp. E1876-E1885 View PDFCrossRefView Record in ScopusGoogle Scholar

[52]V. Sorrentino, M. Romani, L. Mouchiroud, J.S. Beck, H. Zhang, D. D’Amico, et al.Enhancing mitochondrial proteostasis reduces amyloid-beta proteotoxicityNature, 552 (2017), pp. 187-193 View PDFCrossRefView Record in ScopusGoogle Scholar

[53]E. Sidransky, M.A. Nalls, J.O. Aasly, J. Aharon-Peretz, G. Annesi, E.R. Barbosa, et al.Multicenter analysis of glucocerebrosidase mutations in Parkinson’s diseaseN. Engl. J. Med., 361 (2009), pp. 1651-1661View Record in ScopusGoogle Scholar

[54]M. Scheibye-Knudsen, S.J. Mitchell, E.F. Fang, T. Iyama, T. Ward, J. Wang, et al.A high-fat diet and NAD(+) activate Sirt1 to rescue premature aging in cockayne syndromeCell Metabol., 20 (2014), pp. 840-855ArticleDownload PDFView Record in ScopusGoogle Scholar

[55]K.J. Bitterman, R.M. Anderson, H.Y. Cohen, M. Latorre-Esteves, D.A. SinclairInhibition of silencing and accelerated aging by nicotinamide, a putative negative regulator of yeast sir2 and human SIRT1J. Biol. Chem., 277 (2002), pp. 45099-45107ArticleDownload PDFView Record in ScopusGoogle Scholar

[56]C.M. Gallo, D.L. Smith Jr., J.S. SmithNicotinamide clearance by Pnc1 directly regulates Sir2-mediated silencing and longevityMol. Cell Biol., 24 (2004), pp. 1301-1312 View PDFView Record in ScopusGoogle Scholar

[57]K. Schmeisser, J. Mansfeld, D. Kuhlow, S. Weimer, S. Priebe, I. Heiland, et al.Role of sirtuins in lifespan regulation is linked to methylation of nicotinamideNat. Chem. Biol., 9 (2013), pp. 693-700 View PDFCrossRefView Record in ScopusGoogle Scholar

[58]A. van der Horst, J.M. Schavemaker, W. Pellis-van Berkel, B.M. BurgeringThe Caenorhabditis elegans nicotinamidase PNC-1 enhances survivalMech. Ageing Dev., 128 (2007), pp. 346-349ArticleDownload PDFView Record in ScopusGoogle Scholar

[59]S.J. Mitchell, M. Bernier, M.A. Aon, S. Cortassa, E.Y. Kim, E.F. Fang, et al.Nicotinamide improves aspects of healthspan, but not lifespan, in miceCell Metabol., 27 (2018), pp. 667-676 e4ArticleDownload PDFView Record in ScopusGoogle Scholar

[60]P.A. Williams, J.M. Harder, N.E. Foxworth, K.E. Cochran, V.M. Philip, V. Porciatti, et al.Vitamin B3 modulates mitochondrial vulnerability and prevents glaucoma in aged miceScience, 355 (2017), pp. 756-760 View PDFCrossRefView Record in ScopusGoogle Scholar

[61]J. Morales, L. Li, F.J. Fattah, Y. Dong, E.A. Bey, M. Patel, et al.Review of poly (ADP-ribose) polymerase (PARP) mechanisms of action and rationale for targeting in cancer and other diseasesCrit. Rev. Eukaryot. Gene Expr., 24 (2014), pp. 15-28View Record in ScopusGoogle Scholar

[62]P. Bai, C. Canto, H. Oudart, A. Brunyanszki, Y. Cen, C. Thomas, et al.PARP-1 inhibition increases mitochondrial metabolism through SIRT1 activationCell Metabol., 13 (2011), pp. 461-468ArticleDownload PDFView Record in ScopusGoogle Scholar

[63]S. Martire, A. Fuso, D. Rotili, I. Tempera, C. Giordano, I. De Zottis, et al.PARP-1 modulates amyloid beta peptide-induced neuronal damagePLoS One, 8 (2013), Article e72169 View PDFCrossRefView Record in ScopusGoogle Scholar

[64]C. Cosi, P. Chopin, M. MarienBenzamide, an inhibitor of poly(ADP-ribose) polymerase, attenuates methamphetamine-induced dopamine neurotoxicity in the C57B1/6N mouseBrain Res., 735 (1996), pp. 343-348ArticleDownload PDFView Record in ScopusGoogle Scholar

[65]X.L. Wu, P. Wang, Y.H. Liu, Y.X. XueEffects of poly (ADP-ribose) polymerase inhibitor 3-aminobenzamide on blood-brain barrier and dopaminergic neurons of rats with lipopolysaccharide-induced Parkinson’s diseaseJ. Mol. Neurosci., 53 (2014), pp. 1-9 View PDFCrossRefView Record in ScopusGoogle Scholar

[66]T.M. Kauppinen, S.W. Suh, Y. Higashi, A.E. Berman, C. Escartin, S.J. Won, et al.Poly(ADP-ribose)polymerase-1 modulates microglial responses to amyloid betaJ. Neuroinflamm., 8 (2011), p. 152 View PDFCrossRefView Record in ScopusGoogle Scholar

[67]A.S. Mandir, S. Przedborski, V. Jackson-Lewis, Z.Q. Wang, C.M. Simbulan-Rosenthal, M.E. Smulson, et al.Poly(ADP-ribose) polymerase activation mediates 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP)-induced parkinsonismProc Natl. Acad. Sci. U. S. A., 96 (1999), pp. 5774-5779 View PDFView Record in ScopusGoogle Scholar

[68]H. Yokoyama, H. Kuroiwa, T. Tsukada, H. Uchida, H. Kato, T. ArakiPoly(ADP-ribose)polymerase inhibitor can attenuate the neuronal death after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in miceJ. Neurosci. Res., 88 (2010), pp. 1522-1536View Record in ScopusGoogle Scholar

[69]T.W. Kim, H.M. Cho, S.Y. Choi, Y. Suguira, T. Hayasaka, M. Setou, et al.(ADP-ribose) polymerase 1 and AMP-activated protein kinase mediate progressive dopaminergic neuronal degeneration in a mouse model of Parkinson’s diseaseCell Death Dis., 4 (2013), p. e919 View PDFCrossRefView Record in ScopusGoogle Scholar

[70]E.N. ChiniCD38 as a regulator of cellular NAD: a novel potential pharmacological target for metabolic conditionsCurr. Pharmaceut. Des., 15 (2009), pp. 57-63 View PDFCrossRefView Record in ScopusGoogle Scholar

[71]P. Aksoy, T.A. White, M. Thompson, E.N. ChiniRegulation of intracellular levels of NAD: a novel role for CD38Biochem. Biophys. Res. Commun., 345 (2006), pp. 1386-1392ArticleDownload PDFView Record in ScopusGoogle Scholar

[72]M.T. Barbosa, S.M. Soares, C.M. Novak, D. Sinclair, J.A. Levine, P. Aksoy, et al.The enzyme CD38 (a NAD glycohydrolase, EC 3.2.2.5) is necessary for the development of diet-induced obesityFASEB J., 21 (2007), pp. 3629-3639 View PDFCrossRefView Record in ScopusGoogle Scholar

[73]O.A. Adebanjo, H.K. Anandatheerthavarada, A.P. Koval, B.S. Moonga, G. Biswas, L. Sun, et al.A new function for CD38/ADP-ribosyl cyclase in nuclear Ca2+ homeostasisNat. Cell Biol., 1 (1999), pp. 409-414View Record in ScopusGoogle Scholar

[74]M. Scheibye-Knudsen, A. Tseng, M. Borch Jensen, K. Scheibye-Alsing, E.F. Fang, T. Iyama, et al.Cockayne syndrome group A and B proteins converge on transcription-linked resolution of non-B DNAProc Natl. Acad. Sci. U. S. A., 113 (2016), pp. 12502-12507 View PDFCrossRefView Record in ScopusGoogle Scholar

[75]C. Escande, V. Nin, N.L. Price, V. Capellini, A.P. Gomes, M.T. Barbosa, et al.Flavonoid apigenin is an inhibitor of the NAD+ ase CD38: implications for cellular NAD+ metabolism, protein acetylation, and treatment of metabolic syndromeDiabetes, 62 (2013), pp. 1084-1093 View PDFCrossRefView Record in ScopusGoogle Scholar

[76]D. Jin, H.X. Liu, H. Hirai, T. Torashima, T. Nagai, O. Lopatina, et al.CD38 is critical for social behaviour by regulating oxytocin secretionNature, 446 (2007), pp. 41-45 View PDFCrossRefView Record in ScopusGoogle Scholar

[77]K. Hayakawa, E. Esposito, X. Wang, Y. Terasaki, Y. Liu, C. Xing, et al.Transfer of mitochondria from astrocytes to neurons after strokeNature, 535 (2016), pp. 551-555 View PDFCrossRefView Record in ScopusGoogle Scholar

[78]J. Camacho-Pereira, M.G. Tarrago, C.C.S. Chini, V. Nin, C. Escande, G.M. Warner, et al.CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanismCell Metabol., 23 (2016), pp. 1127-1139ArticleDownload PDFView Record in ScopusGoogle Scholar

[79]E. Blacher, T. Dadali, A. Bespalko, V.J. Haupenthal, M.O. Grimm, T. Hartmann, et al.Alzheimer’s disease pathology is attenuated in a CD38-deficient mouse modelAnn. Neurol., 78 (2015), pp. 88-103 View PDFCrossRefView Record in ScopusGoogle Scholar

[80]P. PissiosNicotinamide N-methyltransferase: more than a vitamin B3 clearance enzymeTrends Endocrinol. Metabol., 28 (2017), pp. 340-353ArticleDownload PDFView Record in ScopusGoogle Scholar

[81]M. Liu, L. Li, J. Chu, B. Zhu, Q. Zhang, X. Yin, et al.Serum N(1)-methylnicotinamide is associated with obesity and diabetes in ChineseJ Clin. Endocrinol. Metabol., 100 (2015), pp. 3112-3117 View PDFCrossRefView Record in ScopusGoogle Scholar

[82]A. Kannt, A. Pfenninger, L. Teichert, A. Tonjes, A. Dietrich, M.R. Schon, et al.Association of nicotinamide-N-methyltransferase mRNA expression in human adipose tissue and the plasma concentration of its product, 1-methylnicotinamide, with insulin resistanceDiabetologia, 58 (2015), pp. 799-808 View PDFCrossRefView Record in ScopusGoogle Scholar

[83]D. Kraus, Q. Yang, D. Kong, A.S. Banks, L. Zhang, J.T. Rodgers, et al.Nicotinamide N-methyltransferase knockdown protects against diet-induced obesityNature, 508 (2014), pp. 258-262 View PDFCrossRefView Record in ScopusGoogle Scholar

[84]A. Kannt, S. Rajagopal, S.V. Kadnur, J. Suresh, R.K. Bhamidipati, S. Swaminathan, et al.A small molecule inhibitor of Nicotinamide N-methyltransferase for the treatment of metabolic disordersSci. Rep., 8 (2018), p. 3660 View PDFView Record in ScopusGoogle Scholar

[85]D.V. Titov, V. Cracan, R.P. Goodman, J. Peng, Z. Grabarek, V.K. MoothaComplementation of mitochondrial electron transport chain by manipulation of the NAD+/NADH ratioScience, 352 (2016), pp. 231-235 View PDFCrossRefView Record in ScopusGoogle Scholar

[86]V. Cracan, D.V. Titov, H. Shen, Z. Grabarek, V.K. MoothaA genetically encoded tool for manipulation of NADP(+)/NADPH in living cellsNat. Chem. Biol., 13 (2017), pp. 1088-1095 View PDFCrossRefView Record in ScopusGoogle Scholar

[87]X.A. Cambronne, M.L. Stewart, D. Kim, A.M. Jones-Brunette, R.K. Morgan, D.L. Farrens, et al.Biosensor reveals multiple sources for mitochondrial NAD(+)Science, 352 (2016), pp. 1474-1477 View PDFCrossRefView Record in ScopusGoogle Scholar

[88]Y. Zhao, Q. Hu, F. Cheng, N. Su, A. Wang, Y. Zou, et al.SoNar, a highly responsive NAD+/NADH sensor, allows high-throughput metabolic screening of anti-tumor agentsCell Metabol., 21 (2015), pp. 777-789ArticleDownload PDFView Record in ScopusGoogle Scholar

[89]L. Liu, X. Su, W.J. Quinn 3rd, S. Hui, K. Krukenberg, D.W. Frederick, et al.Quantitative analysis of NAD synthesis-breakdown fluxesCell Metabol., 27 (2018), pp. 1067-10680 e5 View PDFCrossRefView Record in ScopusGoogle Scholar

[90]S.A. Trammell, M.S. Schmidt, B.J. Weidemann, P. Redpath, F. Jaksch, R.W. Dellinger, et al.Nicotinamide riboside is uniquely and orally bioavailable in mice and humansNat. Commun., 7 (2016), p. 12948 View PDFView Record in ScopusGoogle Scholar

[91]R.W. Dellinger, S.R. Santos, M. Morris, M. Evans, D. Alminana, L. Guarente, et al.Repeat dose NRPT (nicotinamide riboside and pterostilbene) increases NAD(+) levels in humans safely and sustainably: a randomized, double-blind, placebo-controlled studyNPJ Aging Mech. Dis., 3 (2017), p. 17 View PDFView Record in ScopusGoogle Scholar

[92]C.R. Martens, B.A. Denman, M.R. Mazzo, M.L. Armstrong, N. Reisdorph, M.B. McQueen, et al.Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD(+) in healthy middle-aged and older adultsNat. Commun., 9 (2018), p. 1286 View PDFView Record in ScopusGoogle Scholar

[93]C.C. Chini, A.M. Guerrico, V. Nin, J. Camacho-Pereira, C. Escande, M.T. Barbosa, et al.Targeting of NAD metabolism in pancreatic cancer cells: potential novel therapy for pancreatic tumorsClin. Cancer Res., 20 (2014), pp. 120-130 View PDFView Record in ScopusGoogle Scholar

[94]H.Q. Ju, Z.N. Zhuang, H. Li, T. Tian, Y.X. Lu, X.Q. Fan, et al.Regulation of the Nampt-mediated NAD salvage pathway and its therapeutic implications in pancreatic cancerCancer Lett., 379 (2016), pp. 1-11ArticleDownload PDFView Record in ScopusGoogle Scholar

[95]E.M. Fivenson, S. Lautrup, N. Sun, M. Scheibye-Knudsen, T. Stevnsner, H. Nilsen, et al.Mitophagy in neurodegeneration and agingNeurochem. Int., 109 (2017), pp. 202-209ArticleDownload PDFView Record in ScopusGoogle Scholar

Originally published here: https://www.sciencedirect.com/science/article/pii/S2468501118300063

COVID-19: NAD+ deficiency

COVID-19: NAD+ deficiency may predispose the aged, obese and type2 diabetics to mortality through its effect on SIRT1 activity

Abstract

The SARS-CoV-2 hyperinflammatory response is associated with high mortality. This hypothesis suggests that a deficiency of nicotinamide adenine dinucleotide (NAD+) may be the primary factor related to the SARS-Cov-2 disease spectrum and the risk for mortality, as subclinical nutritional deficiencies may be unmasked by any significant increase in oxidative stress.

NAD+ levels decline with age and are also reduced in conditions associated with oxidative stress as occurs with hypertension, diabetes and obesity. These groups have also been observed to have high mortality following infection with COVID-19. Further consumption of NAD+ in a pre-existent depleted state is more likely to cause progression to the hyperinflammatory stage of the disease through its limiting effects on the production of SIRT1.

This provides a unifying hypothesis as to why these groups are at high risk of mortality and suggests that nutritional support with NAD+ and SIRT1 activators, could minimise disease severity if administered prophylactically and or therapeutically. The significance of this, if proven, has far-reaching consequences in the management of COVID-19 especially in third world countries, where resources and finances are limited.

Background

COVID-19 may be asymptomatic or manifest in 3 clinical phases, an initial upper respiratory tract infection, with a few patients thereafter progressing to a pneumonic phase, and an even smaller number to the hyperinflammatory phase which may be lethal [1]. The aim of any therapy would be to intervene at an early stage, either prophylactically or therapeutically, to prevent progression of the disease to a point where mechanical ventilation (MV) is required, or significant organ dysfunction occurs [2].

Risk factors for a poor outcome include older age, comorbidity (in particular diabetes, hypertension and cardiac disease), non-asthmatic respiratory disease, obesity, immunosuppression and male sex [2][3]. The independent associations of advancing age, male sex, chronic respiratory conditions (though not well controlled asthma), chronic cardiac and chronic neurological disease with in-hospital mortality, are in line with other international reports [4]. It is difficult however to determine why these conditions specifically are linked to mortality.

Docherty et al. report that severe SARS-CoV-2 infections are rare in those under 18 years of age, comprising only 1.4% of those admitted to hospital. Only 0.8% of those in this study were under 5 years of age, and this “J” shaped age distribution was starkly different from the “U” shaped distribution seen in seasonal influenza [5]. It has not been clear from observational studies however, why SARS-CoV-2 mostly spared children, but it has been speculated that it is due to differential expression of the ACE2 receptor in the developing lung [6]. Similarly, pregnancy has not been reported to be associated with mortality, in contrast to the situation with influenza [4][7].

While the general concept of an excessive or uncontrolled release of pro-inflammatory cytokines is well known, an actual definition of what a hyperinflammatory response or “Cytokine Storm” is, is lacking. Furthermore, there is a poor understanding of the molecular events that precipitate this response and the contribution it makes to pathogenesis. It is also not known what therapeutic strategies might be used to prevent this catastrophic progression of the disease or lessen its severity once initiated [8].

In this phase, there is an unbalanced and exacerbated inflammatory response with the release of inter alia, tumor necrosis factor (TNF-α), interleukin 1β (IL-1β), interleukin 6 (IL-6), as pro-inflammatory mediators together with interleukin 10 (IL-10) and interferon β as anti-inflammatory mediators. The complex interactions between TNF-α, the interleukins, chemokines and interferons in SARS-CoV-2 are currently poorly understood; however, they are associated with and related to a significant viraemia [9][10].

The fact that most international studies have indicated that certain risk factors were common suggested that a similar systemic abnormality might be present in those at high risk, predisposing to severe illness or mortality.

In this context, the nicotinamide adenine dinucleotide (NAD+)- and zinc-dependent molecule, the Silent Information Regulator 1 (SIRT1) represents a potential common thread in the aetiology of the hyperinflammatory response and increased mortality.

SARS-CoV-2 binding

SARS-CoV-2 targets and binds to the angiotensin-converting enzyme 2 receptor (ACE2R), a membrane-associated aminopeptidase also expressed in the vascular endothelium, renal and cardiovascular tissue, and small intestine, testis, and respiratory epithelia [11]. The ACE2R acts as the host cell receptor for the virus which binds via the spike protein on the viral capsid [12]. This stimulates clathrin-dependent endocytosis of both the ACE2R and virus, events that are essential for infectivity. This process induces ADAM 17 activity which reduces expression of ACE2 on the cell surface [13].

Nicotinamide adenine dinucleotide (NAD+)

NAD+ is a cofactor found in every cell of the body, and it is involved in multiple metabolic pathways. It is a fundamental housekeeping molecule that catalyses electron transfer in metabolic reduction–oxidation reactions, functioning as an electron shuttle in the production of adenosine triphosphate (ATP).

Increased age is a strong predictor of SARS-CoV-2-associated in-hospital mortality after adjusting for comorbidity [6]. Older patients have also been identified as having the lowest levels of NAD+ [14], while, conversely, those with the lowest risk, infants and children have the highest levels.

The decline in NAD+ levels with ageing is mainly dependent on CD38, a 45 kDa transmembrane molecule, encoded on chromosome 4. In leukocytes, it acts as a receptor in adhesion and signalling pathways [15]. CD38 expression is increased with insulin resistance, and may exacerbate the age-dependent decline of NAD+ [9]. NAD+ and NADP profoundly affect age-influencing factors such as oxidative stress and mitochondrial activity, and NAD+-dependent sirtuins also mediate the ageing process [10]. As humans age, antioxidant defence mechanisms such as glutathione production are also depleted and the associated increase in reactive oxidative species (ROS) causes all cells [16] to enter a state of pseudohypoxia in which the ratio of NAD+/NADP declines [17][18][19].

Oxidative stress also activates the NAD+-dependent enzyme, poly ADP ribose polymerase 1 (PARP1) [20]. Hyperactivity of PARP1 results in depletion of cellular NAD+ pools, leading to ATP deficiency, energy loss, and subsequent cell death. These processes have the potential to enhance the pro-inflammatory cascade.

NAD+ deficiency impairs SIRT1 function [21] and its successful activation. Whereas extreme niacin deficiency is associated with the development of pellagra, more subtle decreases occur in diabetes, ageing and hypertension with resultant attenuation of responsiveness to inflammatory stimuli [22].

Silent Information Regulator 1 (SIRT1)

Sirtuins are an ancient family of seven NAD+-dependent deacylase and mono-ADP-ribosyl transferase signalling proteins that are intrinsically involved in metabolic regulation and cellular homeostasis. Of particular interest is SIRT1, which downregulates ADAM 17 (A Disintegrin and Metalloproteinase Domain 17), also called TNF-α converting enzyme (TACE), by increasing expression of TIMP3 the gene that encodes for tissue metalloproteinase inhibitor 3 [23]. In so doing it decreases levels of TNF-α, IL-1b and IL-6. An increase in TNF-α causes SIRT1 to down-regulate ADAM 17, thereby controlling TNF-α formation in a negative feedback loop that secondarily influences IL-1b and IL-6 production, which are dependent on TNF-α [23].

SIRT1 is known to play a crucial role in obesity-associated metabolic diseases, cancer, ageing, cellular senescence, cardiac ageing and stress, prion-mediated neurodegeneration, inflammatory signalling in response to environmental stress, embryonal development of the heart, brain, spinal cord and dorsal root ganglia, and placental cell survival [24]. In its inactive or open state, it contains a Zn++ module and an NAD+ -binding site [25].

Whereas certain conditions such as ulcerative colitis, Crohn’s disease, short bowel syndrome, renal failure, alcoholism, and inadequate meat intake are specifically associated with zinc deficiency there is evidence that zinc intake among older adults might be marginal. An analysis of the Third National Health and Nutrition Examination Survey (NHANES III), 1988–1994 data found that 35–45% of adults aged 60 years or older had a zinc intake below estimated average requirements [26].

When NAD+ binds to the SIRT1 molecule in the presence of the Zn++ -binding module, it undergoes a structural change, enveloping the NAD+ molecule and causing it to be “closed” or activated [25]. The presence of both the Zn++ and the NAD+ moieties are imperative for its function.

SIRT1 downregulates ADAM17 and cytokine production

ADAM17 is a proteinase encoding gene. TNF-α and the cytokine receptor for IL-6 must be proteolytically cleaved in order to be systemically active, and ADAM17 provides this function. If ADAM17 expression is not downregulated by SIRT1, TNF-α and IL-6 are released, resulting in an uncontrolled hyperinflammatory response as may occur with COVID-19 [23][27][28][29][30]. SIRT 1, by inhibition of ADAM17 and thereby TNF-α and IL-6, performs an anti-inflammatory function [31][32][33][34][35][36][37][38].

If oxidative stress is severe, increased ADAM17 attempts to ameliorate tissue injury by converting active iron (Fe2+) to its inert form (Fe3+) which is stored in hepatocytes and macrophages and as ferritin by means of the Fenton reaction (Fe2+ + H2O2 → Fe3+ + HO + OH), (Fe3+ + H2O2 → Fe2+ + HO2  + H+). This also potentially transforms haemoglobin to methaemoglobin, reducing its capacity to bind to oxygen [39].Go to:

COVID-19 replication and SIRT1

SIRT1 not only controls and modifies the inflammatory response, but along with the Sirtuin family (SIRT1–7) is also a primary defence against DNA and RNA viral pathogens [40]. In some respiratory infections and cardiovascular conditions, SIRT1 promotes autophagy (the destruction of damaged or redundant cellular components occurring in vacuoles within the cell), and in so doing inhibits apoptosis and provides protection against hypoxic stress [37][38][39][40].

Upregulation of SIRT1 directly decreases viral replication and inhibits the activation of ADAM17, thereby decreasing TNF-α, IL-1b and IL-6. Conversely depletion of SIRT1 allows for increased viral replication with little or no inhibition of ADAM17 activity, causing uncontrolled increases in TNF-α, IL-6 and IL-1b. Whereas an increase in TNF-α would usually increase SIRT1 activity to downregulate ADAM17, in the presence of a deficiency of NAD+ or Zn++, this would not occur due to insufficient activation of SIRT1, causing an unchecked increase in TNF-α.

In both obesity and type 2 diabetes mellitus, intracellular NAD+ levels are decreased in multiple tissues, including adipose tissue, skeletal muscle, liver and the hypothalamus. [41] Furthermore, both conditions are characterised by low-grade inflammation associated with activation of both IL6 and TNF-α [42][43]. Obesity or type 2 diabetes mellitus would increase the risk for cytokine storm due to an inability to activate SIRT1.

SIRT1 maintains vascular endothelial function, preventing or reducing the potential for the metabolic syndrome, ischaemia–reperfusion injury and inflammation in obesity. With increasing age however, NAD+ levels and sirtuin activity decline and this is exacerbated by obesity and sedentary lifestyles [22]. SIRT1 is an effective inhibitor of oxidative stress in vascular endothelial cells (EC) [44] via various signalling pathways [45].

The endothelial glycocalyx (EG) is a web of membrane-bound glycoproteins on the luminal side of endothelial cells, associated with various glycosaminoglycans that cover the vascular endothelium [46]. The EG separates cellular blood components from the endothelium and maintains osmotic tension of the intravascular compartment [44][45].

Conditions causing damage to, and shedding or fragmentation of the EG, (as seen in SARSCoV-2 under severe oxidative stress induced by the hyperinflammatory response), exposes the endothelium, allowing adhesion, clumping and activation of platelets with degranulation and release of vasoactive substances. The EG has anticoagulant properties as it is a binding site for mediators such as heparin cofactor II, antithrombin, thrombomodulin and tissue factor pathway inhibitor (TFPI). Heparin cofactor II and dermatan sulphate inhibit thrombin, and antithrombin activity is enhanced when bound to heparan sulphate. Conversely, exposure of the endothelial cell surface protein, thrombomodulin, which contains a cofactor for thrombin, chondroitin sulphate, promotes coagulation via activation of tissue factor [46] as seen in SAR-CoV-2.

The EG is already compromised in systemic inflammatory states, such as diabetes, hyperglycaemia, surgery, trauma and sepsis [46]. Under conditions of more severe oxidative stress, as in the hyperinflammatory response, widespread damage may lead to its destruction, with the occurrence of capillary leak and oedema formation, accelerated inflammation, platelet aggregation, hypercoaguability and a loss of vascular responsiveness [47]. Inflammatory mediators that are implicated in this process are TNF-α, bradykinin, C-reactive protein and mast cell tryptase.

Given the above, it is possible that activation of SIRT1 may be a crucial factor in the prevention of the hyperinflammatory response and may be necessary for a successful defence against viral attack. Vulnerable patient groups would potentially be less likely or unable to ensure sufficient activation of SIRT1 due to low NAD+ levels or associated nutritional deficiencies including Zn++, and as such contribute to an inability to control viral replication and reduce the uncontrolled expression of pro-inflammatory cytokines.Go to:

Conclusion

The SARS-CoV-2 hyperinflammatory response is associated with high mortality. A deficiency of NAD+, in the context of an elevated CD38, may be the primary factor related to the SARS-Cov-2 disease spectrum and the risk of mortality, as subclinical nutritional deficiencies may be unmasked by any significant increase in oxidative stress.

NAD+ levels decline with age and are also reduced in conditions associated with oxidative stress as occurs with hypertension, diabetes and obesity. These same groups have also been observed to have high mortality following infection with COVID-19. Further consumption of NAD+ in a pre-existent depleted state is more likely to cause progression to the hyperinflammatory stage of the disease through its limiting effects on the production of SIRT1.

Given that activation of SIRT1 is dependent on the availability of NAD+ and zinc and that high levels of oxidative stress deplete NAD+, thereby decreasing SIRT1 activity, nutritional support with NAD+ precursors and SIRT1 activators, could minimise disease severity if administered prophylactically and or therapeutically. The significance of this hypothesis, if proven, has far-reaching consequences in the management of COVID-19 especially in third world countries, where resources and finances are limited.Go to:

Grants and support

NA.Go to:

Hypothesis

We hypothesize that reduced Nicotinamide Adenine Dinucleotide (NAD+) levels with consequent deficient activity of the NAD+ dependent molecule SIRT1, which modulates cytokine production, may be the factor that predisposes the aged, obese, type 2 diabetics and other vulnerable groups to an increased mortality.Go to:

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.Go to:

References

1. Siddiqi H.K., Mehra M.R. COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal. J Heart Lung Transplant. 2020;39:405–407. [PMC free article] [PubMed] [Google Scholar]

2. Richards G., Mer M., Schleicher G., Stacey S. COVID-19 and the rationale for pharmacotherapy: a south african perspective. Wits J Clin Med. 2020;2:11. [Google Scholar]

3. The OpenSAFELY Collaborative: Williamson E, Walker AJ, Bhaskaran KJ et al. OpenSAFELY: factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients. medRxiv preprint. doi: 10.1101/2020.05.06.20092999. [CrossRef]

4. Clohisey S, Baillie JK. Host susceptibility to severe influenza A virus infection. Critical Care 2019; 23 pNA Accessed 29/6/20. [PMC free article] [PubMed]

5. Myles P.R., Semple M.G., Lim W.S. Predictors of clinical outcome in a national hospitalised cohort across both waves of the influenza A/H1N1 pandemic 2009–2010 in the UK. Thorax. 2012;67:709–717. [PMC free article] [PubMed] [Google Scholar]

6. A. Docherty, E. Harrison, C. Green, et al., Features of 16,749 hospitalised UK patients with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol (2020).

7. Nguyen-Van-Tam J.S., Openshaw P.J.M., Hashim A. Risk factors for hospitalisation and poor outcome with pandemic A/H1N1 influenza: United Kingdom first wave (May-September 2009) Thorax. 2010;65:645–651. [PMC free article] [PubMed] [Google Scholar]

8. Tisoncik J.R., Korth M.J., Simmons C.P., Farrar J., Martin T.R., Katze M.G. Into the eye of the cytokine storm. Microbiol Mol Biol Rev. 2012;76:16–32. [PMC free article] [PubMed] [Google Scholar]

9. Schultz M.B., Sinclair D.A. Why NAD(+) declines during aging: It’s destroyed. Cell Metab. 2016;23:965–966. [PMC free article] [PubMed] [Google Scholar]

10. Massudi H., Grant R., Farnsworth B., Braidy N., Guest J., Farnsworth B. Age-associated changes in oxidative stress and NAD+ metabolism in human tissue. Plos 1. 2012;7:e 42357. [PMC free article] [PubMed] [Google Scholar]

11. Jia H.P., Look D.C., Shi L., Shi M.L., Hickey M. ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia. J Virol. 2005;79:14614–14621. [PMC free article] [PubMed] [Google Scholar]

12. Magrone T., Magrone M., Jirillo E. Focus on receptors for coronaviruses with special reference to Angiotensin-converting Enzyme 2 as a potential drug target – A Perspective. Endocr Metab Immune Disord Drug Targets. 2020 Apr doi: 10.2174/1871530320666200427112902. [PubMed] [CrossRef] [Google Scholar]

13. Clarke N.E., Turner A.J. Angiotensin-converting enzyme 2: the first decade. Int J Hypertens. 2012;2012:307315. [PMC free article] [PubMed] [Google Scholar]

14. Mueller A.L., McNamara M.S., Sinclair D.A. Why does COVID-19 disproportionately affect older people? Aging (Albany NY) 2020;12:9959–9981. doi: 10.18632/aging.10334. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

15. Matutes E. New additions to antibody panels in the characterisation of chronic lymphoproliferative disorders. J Clin Pathol. 2002;55:180–183. [PMC free article] [PubMed] [Google Scholar]

16. Lee H.J., Yang S.J. Aging-related correlation between serum sirtuin 1 activities and basal metabolic rate in women, but not in men. Clin Nutr Res. 2017;6:18–26. [PMC free article] [PubMed] [Google Scholar]

17. Richards G.A., Van Antwerpen V.L., Hunter S., Theron A.J., van der Merwe C., van der Walt R. Aging and cigarette smoking are associated with decreased glutathione levels in humans. S Afri J Sci. 1996;924:45–447. [Google Scholar]

18. Ying W. NAD+/NADH and NADP+/NADPH in cellular functions and cell death: regulation and biological consequences. Antioxid Redox Signal. 2008;10:179–206. [PubMed] [Google Scholar]

19. Blacker T.S., Duchen MR. Investigating mitochondrial redox state using NADH and NADPH autofluorescence. Free Rad Biol Med. 2016;100:53–65. [PMC free article] [PubMed] [Google Scholar]

20. Guarente L. Calorie restriction and sirtuins revisited. Genes Dev. 2013;27:2072–2085. [PMC free article] [PubMed] [Google Scholar]

21. Delage B. Linus Pauling Institute. Niacin. 2017 https://lpi.oregonstate.edu/mic/vitamins/niacin. (accessed 29/6/20).

22. Kane A.E., Sinclair D.A. Sirtuins and NAD(+) in the development and treatment of metabolic and cardiovascular diseases. Circ Res. 2018;14:868–885. doi: 10.1161/CIRCRESAHA.118.312498. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

23. Fontani F., Domazetovic V., Marcucci T., Vincenzini M.T., Lantomasi T. MMPs, ADAMs and their natural inhibitors in inflammatory bowel disease: involvement of oxidative stress. J Clin Gastroenterol Treat. 2017;3:039 https://clinmedjournals.org/articles/jcgt/journal-of-clinical-gastroenterology-and-treatment-jcgt-3-039.pdf [Google Scholar]

24. Rahman S., Islam R. Mammalian Sirt1: insights on its biological functions. Cell Commun Signal. 2011;9:11. [PMC free article] [PubMed] [Google Scholar]

25. Davenport A.M., Huber F.M., Hoelz A. Structural and functional analysis of human SIRT1. J Mol Biol. 2014;426:526–541. [PMC free article] [PubMed] [Google Scholar]

26. Pilch S.M. Analysis of zinc data from the second national health and nutrition examination survey (NHANES II) J Nutr. 1985;115:1393–1397. doi: 10.1093/jn/115.11.1393. [PubMed] [CrossRef] [Google Scholar]

27. Cardellini M., Menghini R., Martelli E., Casagrande V., Marino A., Rizza S. TIMP3 is reduced in atherosclerotic plaques from subjects with type 2 diabetes and increased by SirT1. Diabetes. 2009;58:2396–2401. doi: 10.2337/db09-0280. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

28. Shin M.R., Kang S.K., Kim Y.S., Lee S.Y., Hong S.C., Kim E.C. TNF-α and LPS activate angiogenesis via VEGF and SIRT1 signalling in human dental pulp cells. Int Endod J. 2015;48:705–716. [PubMed] [Google Scholar]

29. Xie J., Zhang X., Zhang L. Negative regulation of inflammation by SIRT1. Pharmacol Res. 2013;67:60–67. [PubMed] [Google Scholar]

30. Yoo C.-H., Yeom J.-H., Heo J.-J., Song E.-K., Lee S.-I., Han M.-K. Interferon β protects against lethal endotoxic and septic shock through SIRT1 upregulation. Sci Rep. 2014;4:4220. [PMC free article] [PubMed] [Google Scholar]

31. Smith L.M., Wells J.D., Vachharajani V.T., Yoza B.K., McCall C.E., Hoth J.J. SIRT1 mediates a primed response to immune challenge after traumatic lung injury. J Trauma Acute Care Surg. 2015;78:1034–1038. [PMC free article] [PubMed] [Google Scholar]

32. Vachharajani V.T., Liu T., Wang X., Hoth J.J., Yoza B.K., McCall C.E. Sirtuins link inflammation and metabolism. J Immunol Res. 2016;2016:8167273. [PMC free article] [PubMed] [Google Scholar]

33. Chao S.-C., Chen Y.-J., Huang K.-H. Induction of sirtuin-1 signaling by resveratrol induces human chondrosarcoma cell apoptosis and exhibits antitumor activity. Sci Rep. 2017;7:3180. [PMC free article] [PubMed] [Google Scholar]

34. Li Y., Yang X., He Y. Negative regulation of NLRP3 inflammasome by SIRT1 in vascular endothelial cells. Immunobiology. 2017;222:552–561. [PubMed] [Google Scholar]

35. Liu X., Sun T., Shao K. SIRT1mediated regulation of oxidative stress induced by Pseudomonas aeruginosa lipopolysaccharides in human alveolar epithelial cells. Mol Med Rep. 2017;15:813–818. doi: 10.3892/mmr.2016.6045. [PubMed] [CrossRef] [Google Scholar]

36. Yang H., Zhang W., Pan H. SIRT1 activators suppress inflammatory responses through promotion of p65 deacetylation and inhibition of NF-κB activity. PLoS ONE. 2012;7 [PMC free article] [PubMed] [Google Scholar]

37. Yoshizaki T., Milne J.C., Imamura T. SIRT1 exerts anti-inflammatory effects and improves insulin sensitivity in adipocytes. Mol Cell Biol. 2009;29:1363. [PMC free article] [PubMed] [Google Scholar]

38. Yoshizaki T., Schenk S., Imamura T. SIRT1 inhibits inflammatory pathways in macrophages and modulates insulin sensitivity. Am J Physiol Endocrinol Metab. 2010;298:E419–428. [PMC free article] [PubMed] [Google Scholar]

39. Maras J.S., Das S., Sharma S. Iron-overload triggers ADAM-17 mediated inflammation in severe alcoholic hepatitis. Sci Rep. 2018;8:10264. [PMC free article] [PubMed] [Google Scholar]

40. Budayeva H.G., Rowland E.A., Cristea I.M. Intricate roles of mammalian sirtuins in defense against viral pathogens. J Virol. 2016;90:5. [PMC free article] [PubMed] [Google Scholar]

41. Okabe K., Yaku K., Tobe K., Nakagawa T. Implications of altered NAD metabolism in metabolic disorders. J Biomed Sci. 2019;26:34. [PMC free article] [PubMed] [Google Scholar]

42. Esser N., Legrand-Poels S., Piette J., Scheen A.J., Paquot N. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Res Clin Pract. 2014 Aug;105(2):141–150. doi: 10.1016/j.diabres.2014.04.006. [PubMed] [CrossRef] [Google Scholar]

43. Ellulu M.S., Patimah I., Khaza’ai H., Rahmat A., Abed Y. Obesity and inflammation: the linking mechanism and the complications. Arch Med Sci. 2017;13:851–863. [PMC free article] [PubMed] [Google Scholar]

44. Zhang W., Huang Q., Zeng Z., Wu J., Zhang Y., Chen Z. Sirt1 inhibits oxidative stress in vascular endothelial cells. Oxid Med Cell Longevity. 2017;2017:1–8. [PMC free article] [PubMed] [Google Scholar]

45. Woodcock T.E., Woodcock T.M. Revised Starling equation and the glycocalyx model of transvascular fluid exchange: an improved paradigm for prescribing intravenous fluid therapy. Br J Anaesth. 2012;108:384–394. [PubMed] [Google Scholar]

46. Yilmaz O., Afsar B., Ortiz A., Kanbay M. The role of endothelial glycocalyx in health and disease. Clin Kid J. 2019;12:611–619. [PMC free article] [PubMed] [Google Scholar]

47. Iba T., Levy J.H. Derangement of the endothelial glycocalyx in sepsis. J Thromb Haemost. 2019;17:283–294. [PubMed] [Google Scholar]

Originally published here: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7322475/


Statements provided have not been evaluated by the Food and Drug Administration. We do not diagnose, prevent or cure any medical conditions. All infusions and injections are administered by state licensed registered nurses and overseen by our Medical Director, Dr. Daniel La Perriere, a board certified MD, Certified Functional Medicine practitioner through the IFM and Founder of Colorado Concierge Functional Medicine. Some health conditions contraindicate the use of our products. Please consult your physician before beginning injections of any kind.